Chiglitazar reduces fatty liver disease caused by high-fat diet by affecting several body pathways in mice

Chiglitazar significantly improved dyslipidemia and insulin resistance in mice with NAFLD.

• Chiglitazar was administered at doses of 5 mg/kg/d or 10 mg/kg/d to mice after 8 weeks on a high-fat diet.
• The treatment reduced hepatic steatosis, liver inflammation, and oxidative stress in the mice.
• RNA sequencing indicated that chiglitazar affected multiple biological pathways related to fatty acid metabolism and insulin signaling.
• The findings suggest that chiglitazar could be a potential therapeutic option for managing NAFLD.

Simplified